Last reviewed · How we verify
Diuretics plus human albumin
Diuretics promote fluid and sodium excretion while human albumin expands plasma volume and maintains oncotic pressure to counteract fluid shifts.
Diuretics promote fluid and sodium excretion while human albumin expands plasma volume and maintains oncotic pressure to counteract fluid shifts. Used for Ascites in cirrhosis with renal dysfunction, Hepatorenal syndrome, Edema management in hypoalbuminemic states.
At a glance
| Generic name | Diuretics plus human albumin |
|---|---|
| Also known as | Furosemide and antialdosteronic drugs, Human albumin vials 50 cc 20% solution |
| Sponsor | University of Bologna |
| Drug class | Diuretic + colloid combination therapy |
| Modality | Small molecule |
| Therapeutic area | Hepatology; Nephrology; Critical Care |
| Phase | FDA-approved |
Mechanism of action
This combination leverages diuretics to mobilize excess fluid (particularly useful in edematous states) while simultaneously administering human albumin to maintain intravascular oncotic pressure and prevent hypovolemia. The albumin helps retain fluid in the vascular compartment, reducing the risk of acute kidney injury and hemodynamic collapse that can occur with diuretics alone, particularly in patients with cirrhosis or severe hypoalbuminemia.
Approved indications
- Ascites in cirrhosis with renal dysfunction
- Hepatorenal syndrome
- Edema management in hypoalbuminemic states
Common side effects
- Hyperkalemia (if potassium-sparing diuretics used)
- Hyponatremia
- Acute kidney injury
- Infection (albumin-related)
- Electrolyte imbalances
Key clinical trials
- High Dose Albumin in Refractory Ascites (PHASE2)
- Compare the Diuretic Effect With Furosemide vs Furosemide and Albumin Combined in Cirrhotic Patients (PHASE4)
- PREVENTION OF WORSENING RENAL FUNCTION OF INTRAVENUS ALBUMIN IN HEART FAILURE PATIENTS (PHASE3)
- Evaluation of Blood Volume Analysis- Guided Management of Decompensated Heart Failure (NA)
- Midodrine and Albumin in Patients With Refractory Ascites (PHASE3)
- Plasma Exchange in Acute on Chronic Liver Failure (PHASE3)
- Human Albumin for the Treatment of Ascites in Patients With Hepatic Cirrhosis (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Diuretics plus human albumin CI brief — competitive landscape report
- Diuretics plus human albumin updates RSS · CI watch RSS
- University of Bologna portfolio CI